Close Button Icon
Doptelet (avatrombopag) Tablets Logo

You are about to leave DOPTELETHCP.com and go to an external page.

Please note that Sobi is not responsible for the content of the website you are about to visit.

CONTINUE

Go back

This information is intended for healthcare professionals in the United States.

Are you a healthcare professional?

Yes

No
Close Button Icon

Discover the Doptelet Copay Program

Eligible commercially insured patients may qualify for the Doptelet Connect program

What's the program?

  • Eligible patients may pay as little as $0 for each Doptelet prescription
  • Annual maximum benefit up to $15,000

Eligible patients must:

  • Have commercial insurance that covers Doptelet
  • Not be enrolled in any state or federal healthcare program such as Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD), or TRICARE
  • Be 18 years of age or older
  • Be a resident in the United States or a US Territory

How to enroll:

  • Approved pharmacies, healthcare professionals, and Doptelet Connect can enroll patients
  • Patients can enroll themselves as well as their caregivers
  • Please call 1-833-368-2663 Monday–Friday 8 am–8 pm ET for more information

Terms and Conditions

  • Patients pay as little as $0 per prescription. Copay Program has an annual calendar cap of $15,000
  • The Copay Saving Program is void where prohibited by law, taxes, or restricted
  • This offer is non-transferable, no substitutions are permissible, and this offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
  • Sobi, Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice
  • The Patient Copay Program for Doptelet is not insurance and is not intended to substitute for insurance
  • Patients, pharmacists, and healthcare providers must not seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this Copay Program. Patients must not seek reimbursement from any health savings, flexible spending, or other healthcare reimbursement accounts for the amount of assistance received from the Copay Program
  • Certain information pertaining to your use of the Copay Program will be shared with Sobi, Inc., the sponsor of the Copay Program. The information disclosed will include the date the prescription is filled, the number of pills or product dispensed by the pharmacists, and the amount of your copay that will be paid for by using this Copay Program. For more information, please see the Sobi Privacy Policy at https://sobi-northamerica.com/privacy-policy
  • Acceptance in this Program is not conditioned on any past, present, or future purchase, including additional doses
  • Enrollment for the Copay Program is valid through the calendar year
  • Sobi reserves the right to change program terms at any time
Close Button Icon
  • For US healthcare professionals only

  • About Doptelet
  • Efficacy
  • Safety
  • Dosing
  • Access
  • Resources
    • ITP Resources
    • Video Library
  • Request a Rep
  • For US healthcare professionals only

  • Important Safety Information
  • Prescribing Information
  • Patient Information Leaflet
  • For Patients
Doptelet (avatrombopag) Tablets Logo

For US healthcare professionals only

  • About Doptelet
  • Efficacy
  • Safety
  • Dosing
  • Access
  • Resources
    • ITP Resources
    • Video Library
  • Request a Rep

Doptelet is broadly available** and covered on United Healthcare, Express Scripts, CVS Caremark and Aetna.

Formulary status is subject to change and does not imply clinical efficacy or safety.††

Learn more about our
access services here

**

Broadly available: covered for over 50% of patients on plan.

††

For specific information, please contact the patient's insurer. Individual access may vary by geography and plan benefit design. Third-party payment for prescription
drugs is affected by numerous factors, and Sobi makes no representation or guarantee concerning reimbursement or coverage for Doptelet or any other service or item.

Lift Platelets.
No Sweat.

Doptelet® (avatrombopag) is the only oral TPO-RA of its kind that your patients can take anytime based on their schedule, with any food.1-3TPO-RA=thrombopoietin receptor agonist.For adults with thrombocytopenia in chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Doptelet acts fast and lasts1,4*

50K

Raise and maintain

With Doptelet, keep platelet counts lifted at 50,000/μL (primary endpoint).1*

8Days

Lift platelet counts quickly

Most patients reached 50,000 platelets/μL in as few as 8 days with Doptelet (secondary endpoint).1

94%

Reach target levels

94% of patients reached 50,000 platelets/μL at least once during the pivotal trial or open-label extension5

Core study: Efficacy was evaluated in a 6-month, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. Patients had previously received one or more prior chronic ITP therapies and had average screening and baseline platelet counts of <30×109/L. Forty-nine patients were randomized (2:1) to receive either Doptelet (n=32) or placebo (n=17).

  • The primary efficacy endpoint was the cumulative number of weeks of platelet response, defined as a platelet count ≥50×109/L in the absence of rescue therapy, over 6 months of once-daily treatment in adults with chronic ITP. Doptelet-treated patients had a median duration of 12.4 cumulative weeks vs 0 weeks for placebo
  • A secondary efficacy endpoint was the proportion of patients with a platelet response (platelet counts ≥50×109/L) at Day 8. 66% (n=21/32) of Doptelet-treated patients had platelet counts of ≥50,000/μL at Day 8 compared to placebo (n=0/17)

Open-label extension: Patients could enter the open-label extension phase if they completed the 6-month core study, or if they experienced a lack of efficacy during that period. In the extension phase, all patients received titrated Doptelet once daily. Thirty-nine patients (24 Doptelet and 14 placebo) entered the 90-week maintenance period of the extension phase, in which Doptelet dose titration and downward titration of concomitant ITP medications were allowed. At the end of the extension phase, a 4-week, dose-tapering period was followed by a 30-day follow-up after the last dose of Doptelet.4

  • The primary endpoint of the extension study was to assess the long-term safety and efficacy of treatment with Doptelet by measuring platelet response rate, bleeding, and the use of rescue therapy4
  • Exploratory endpoints included the percentage of patients who achieved platelet counts ≥50,000/μL or ≥100,000/μL at any time during the core study and its extension phase. These endpoints were reported in an integrated analysis of the Phase 3 core study and extension phase data. In an integrated analysis of the core study and its extension phase, 93.8% of patients initially randomized to Doptelet and who continued to be treated with Doptelet during the extension phase achieved a platelet count of ≥50,000/μL at any time, compared to 64.7% of placebo patients who rolled-over to Doptelet5,6

Important Safety Information

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Compliance comes with convenience

Food Icon

No food-type restrictions

Patients can take Doptelet with any food (food required); no administration concerns with minerals like calcium or magnesium.1

Liver Icon

No liver monitoring

Doptelet does not require additional liver-function monitoring; no significant hepatotoxicity seen in Doptelet clinical trials.1,4

No Injections Icon

No injections

Doptelet can be taken anytime, anywhere, without adding trips to the doctor (platelet monitoring required).1†‡

Throughout the core study and extension phase, 72.3% of patients were exposed to avatrombopag for at least 32 weeks. In the open-label extension phase for those patients continuing Doptelet treatment, a response was achieved at 44.2% of visits.4,6

After initiating therapy with Doptelet, assess platelet counts weekly until a stable platelet count of ≥50×109/L has been achieved, and then obtain platelet counts monthly thereafter.1

No additional trips to the doctor required for administration.

How Doptelet® (avatrombopag) works

Doptelet helps patients produce more of their own platelets.1

Find out more about the recommended use of TPO-RAs

  • The American Society of Hematology (ASH) guidelines recommend the use of TPO-RAs as a second-line therapy7
  • The updated International Primary ITP Consensus Report recommends the use of TPO-RAs as a therapy subsequent to initial therapy8

Any questions? We’re here to help!

Our support specialists can help answer your questions about Doptelet and access options — call us at 855-4LIFTUP (855-454-3887)

Read about Doptelet efficacy

Doptelet worked to raise platelet counts in patients with ITP in the Phase 3 clinical study. Ready to see the numbers?1

View Efficacy
Doptelet Platelet Character Cheerleader Smiling

References:

  • 1. DOPTELET [package insert]. Durham, NC: AkaRx, Inc.
  • 2. Nplate [prescribing information]. Thousand Oaks, CA: Amgen.
  • 3. Promacta [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
  • 4. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490.
  • 5. Nagalla S, Vredenburg M, Tian W, Allen LF. Platelet response to avatrombopag in patients with chronic immune thrombocytopenia: additional analyses from a phase 3 study and its extension. Blood. 2019;134(suppl 1):1071.
  • 6. Al-Samkari H, Aggarwal K, Vredenburg M, Tian W, Allen LF. Long-term response rates in patients with chronic immune thrombocytopenia treated with avatrombopag: additional analyses from a phase 3 study and its extension phase. Blood. 2019;134(suppl 1):2356.
  • 7. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
  • 8. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817.
INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.

Serious Adverse Reactions

Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

Adverse Reactions

The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Postmarketing Experience

Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

For WAC pricing, visit doptelethcp.com/wac-pricing.

Sobi Rare Strength Logo
Terms of Use
Privacy Policy
Contact Us
Unsubscribe
White YouTube Logo

Doptelet is a registered trademark of AkaRx, Inc.
Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
Doptelet Connect is a trademark of AkaRx, Inc.
© 2022 Sobi, Inc. – All rights reserved

PP-14799   04/22

INDICATION & IMPORTANT
SAFETY INFORMATION
Open ISI Button
Close ISI Button

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Scroll To Top Button

This website uses cookies. By continuing to use this website, you consent to our use of these cookies.

Read more about our use of cookies